- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05361382
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (HEAD)
Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers
Study Overview
Status
Conditions
Detailed Description
This is a longitudinal, multi-site, non-randomized study in which the participants will undergo Flortaucipir and MK-6240 PET scans at baseline and approximately at 18-month follow-up. At each time point, participants will also have an amyloid-β PET scan, magnetic resonance imaging, detailed cognitive tests, and a blood draw for biomarker quantification. The main objectives of this study are standardizing tau PET tracers' outcomes and comparing their performance.
To accomplish our objectives, the investigators propose the following specific aims:
In Aim 1, investigators will standardize tau PET processing methods, convert the tracers to a common scale, compare associations with amyloid-β, atrophy, and cognition, and compare/harmonize Braak staging assessments between tau tracers using cross-sectional data.
In Aim 2, investigators will ascertain the optimal processing method for longitudinal analysis and compare longitudinal changes in tau accumulation obtained with the tau PET radiopharmaceuticals and their associations with changes in amyloid-β, atrophy, and cognition.
In Exploratory Aim 3, investigators will compare cross-sectional and longitudinal Flortaucipir and MK-6240 estimates with plasma phosphorylated tau concentrations.
This study will produce a benchmark dataset to develop methods for tau PET quantification and harmonization.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Tharick Pascoal, MD PhD
- Phone Number: 412-586-9012
- Email: pascoal-research@upmc.edu
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4H1V3
- Recruiting
- McGill University Research Centre for Studies in Aging
-
Contact:
- Pedro Rosa-Neto, MD, PhD
-
-
-
-
-
Barcelona, Spain, 08025
- Not yet recruiting
- Sant Pau Biomedical Research Institute
-
Contact:
- Juan Fortea, MD, PhD
-
-
-
-
California
-
Berkeley, California, United States, 94720
- Recruiting
- Lawrence Berkeley National Laboratory
-
Contact:
- Suzanne Baker, PhD
-
San Francisco, California, United States, 94143
- Recruiting
- University of California San Francisco
-
Contact:
- David Soleimani-Meigooni, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Not yet recruiting
- Mayo Clinic
-
Contact:
- Val Lowe, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63130
- Recruiting
- Washington University in St. Louis
-
Contact:
- Brian A Gordon, PhD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15260
- Recruiting
- University of Pittsburgh
-
Contact:
- Tharick Pascoal, MD PhD
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02912
- Recruiting
- Brown University
-
Contact:
- Hwamee Oh, PhD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Neurological Institute
-
Contact:
- Maria B Pascual, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Have an informant who will be able to provide an independent evaluation of functioning.
- Willing and capable of undergoing repeated MR/PET imaging.
- Fluent in a language approved by the coordinating center.
- At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.
Exclusion criteria:
- Inability to provide informed consent by self or by proxy.
- Pregnant or breastfeeding women.
- Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Individuals across the aging and Alzheimer's disease (AD) spectrum
Approximately 620 individuals (40 young healthy, 280 cognitively unimpaired older, 200 mild cognitive impairment, and 100 Alzheimer's disease dementia) will be enrolled in the HEAD study.
|
Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles.
Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
Other Names:
MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles.
Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques. Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cross-sectional tau PET uptake values
Time Frame: 2 years from enrollment
|
Compare/harmonize cross-sectional tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240.
|
2 years from enrollment
|
Longitudinal change in tau PET uptake values over 18 months
Time Frame: 5 years from enrollment
|
Compare/harmonize change in tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 between baseline and 18-month follow-up assessments.
|
5 years from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Associations of tau PET uptake values with amyloid-β PET uptake values
Time Frame: 5 years from enrollment
|
Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with amyloid-β deposition measurements (SUVR).
|
5 years from enrollment
|
Associations of tau PET uptake values with measures of cognition
Time Frame: 5 years from enrollment
|
Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with cognitive measures assessed from neuropsychological evaluation.
|
5 years from enrollment
|
Associations of tau PET uptake values blood biomarkers
Time Frame: 5 years from enrollment
|
Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with blood-based biomarkers of tau.
|
5 years from enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tharick Pascoal, MD PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY22020056
- R01AG073267 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on 18F-Flortaucipir radiopharmaceutical
-
ITEL Telecomunicazioni SrlAdvice Pharma Group srlNot yet recruitingProstate Cancer | Radiotherapy | Prostatectomy | 18F- Fluorocholine | PSMA PET | Tumor of Prostate
-
Vanderbilt-Ingram Cancer CenterTerminated
-
Tammie L. S. Benzinger, MD, PhDWithdrawnAlzheimer DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedChronic Traumatic EncephalopathyUnited States
-
Neil M Rofsky, MD, MHACompletedAlzheimer Disease | Cognitive DeclineUnited States
-
Avid RadiopharmaceuticalsCompleted
-
University of North Carolina, Chapel HillBoston Children's Hospital; Medical College of Wisconsin; National Football LeagueEnrolling by invitation
-
Avid RadiopharmaceuticalsCompletedAlzheimer DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States